EPA

Quick Summary

EPA (eicosapentaenoic acid, C20:5 n-3) is the long-chain marine omega-3 most strongly associated with anti-inflammation, conditional cardiovascular event reduction, and mood support. It is one of three members of the omega-3 family (with DHA and plant-based ALA); this page treats EPA on its own. For the family overview and the EPA-vs-DHA-vs-ALA framework, see the omega-3 hub.

• What EPA is. A 20-carbon, 5-double-bond omega-3 fatty acid. It is the major precursor of the E-series resolvins (RvE1, RvE2) and 18-HEPE — specialized pro-resolving mediators that actively switch off inflammation rather than merely suppressing it. This places EPA at the center of omega-3's anti-inflammatory and resolution biology.
• Where it comes from. EPA's primary dietary source is oily fish and fish oil (anchovy, sardine, mackerel, herring, salmon) and, in phospholipid form, krill oil. Algae oil is the vegan/vegetarian alternative — not the primary source. Plant-based ALA (flaxseed, chia, walnut) converts to EPA only inefficiently.

What the human-evidence record actually shows:

• Triglyceride lowering — robust and dose-dependent: 15–30% reduction at 2–4 g/day EPA+DHA, largest in people with the highest baseline triglycerides (dose-response meta-analysis, PMID 37264945). This is EPA's established metabolic effect.
• Cardiovascular event reduction is conditional, not universal. Read three trials together. REDUCE-IT (PMID 30415628): 4 g/day pure prescription EPA (icosapent ethyl) cut major cardiovascular events by 25% (hazard ratio 0.75) in statin-treated high-triglyceride patients. VITAL (PMID 30415637): 1 g/day EPA+DHA did not reduce total major cardiovascular events in a general population. STRENGTH (PMID 33190147): 4 g/day EPA+DHA carboxylic acid showed no cardiovascular benefit and a higher rate of new-onset atrial fibrillation. The lesson: dose, form, EPA:DHA ratio, and baseline risk all matter — pure high-dose EPA is not the same as a fish-oil blend.
• Depression — meta-analyses support an antidepressant signal for EPA-predominant formulations (EPA ≥60%) or pure EPA at ≤1 g/day as an adjunct; DHA-predominant formulations do not (PMID 31383846; PMID 26978738).
• Inflammation — omega-3 (EPA+DHA) significantly reduced tender joint count and improved inflammatory and lipid markers in rheumatoid arthritis; the composite DAS28 disease-activity change did not reach statistical significance (meta-analysis, PMID 38922552).

Critical distinction — EPA is not DHA. EPA's evidence concentrates on inflammation, cardiovascular, and mood; DHA's concentrates on brain and retinal structure (fetal development, vision, cognitive maintenance). They are not interchangeable. See the DHA sub-page for the structural side.

Critical distinction — supplement EPA is not prescription icosapent ethyl. The REDUCE-IT result was demonstrated with a 4 g/day prescription drug under physician supervision in a defined high-risk population. Over-the-counter pure-EPA supplements at 1–2 g/day do not replicate that evidence base, and the cardiovascular outcome data should not be transferred to them.

Bottom line: EPA is genuinely useful for specific outcomes — triglycerides, EPA-predominant mood support, inflammation, and (as a prescription drug at high dose, in the right population) cardiovascular event reduction. Its benefits are dose-, form-, and population-dependent, and the null trials are an essential part of the picture.

What is EPA? Chemistry, sources, and the EPA-vs-DHA split

EPA is a 20-carbon, 5-double-bond marine omega-3 and the major precursor of E-series resolvins; its primary dietary source is oily fish and fish oil, with algae oil as the vegan/vegetarian alternative.

EPA (eicosapentaenoic acid) is a long-chain polyunsaturated fatty acid with twenty carbons and five double bonds, the first of which sits at the third carbon from the methyl end of the chain — the structural feature that makes it an "omega-3." It is a member of the omega-3 family alongside DHA (the longer, more unsaturated structural fatty acid) and ALA (the short-chain plant precursor). Where DHA is best understood as a structural fatty acid and ALA as a precursor, EPA is best understood as a signaling and metabolic fatty acid.

EPA at a glance

Where EPA comes from — fish first, algae for plant-based diets

A common and consequential misconception is that EPA is an "algae-only" nutrient. It is not. The practical hierarchy of EPA sources is:

• Oily fish and fish oil — the primary dietary source. Anchovy, sardine, mackerel, herring, and salmon are the richest everyday sources, and fish oil is the form used in most of the randomized-trial evidence. Concentrated fish-oil products can be EPA-skewed (anti-inflammatory and mood-targeted formulations) or balanced.
• Krill oil — phospholipid-bound EPA. Krill oil delivers EPA (modestly EPA-skewed) in phospholipid form along with naturally co-occurring astaxanthin, but at lower total EPA+DHA per softgel than concentrated fish oil.
• Algae oil — the vegan/vegetarian alternative, not the primary source. Microalgae are the original organisms in the marine food chain that synthesize long-chain omega-3 (fish acquire it by eating algae), so algae oil is the appropriate route to direct EPA for people who avoid marine animals. However, most legacy algae oils are DHA-dominant; an EPA-enriched algae strain is required if EPA is the priority. Algae oil is also the contaminant-free option (closed-system fermentation) and the fish-allergy-safe option.
• Plant-source ALA — an inefficient indirect route. Flaxseed, chia, and walnut provide ALA, which the body converts to EPA at roughly 8% (men) to 21% (premenopausal women). ALA is essential and worthwhile, but it is not a dependable way to reach a meaningful EPA intake. See the flaxseed (ALA) sub-page.

The correction worth remembering: EPA is fish-first. Algae oil is the plant-based alternative — important and legitimate, but secondary in the source hierarchy and frequently DHA-dominant unless a specific EPA-enriched strain is chosen.

EPA vs DHA — different molecules, different jobs

The single most useful framing for EPA is the contrast with its sister fatty acid DHA. They co-occur in fish and are often sold together, but their evidence records diverge sharply.

This divergence is not cosmetic. A product's EPA:DHA ratio determines which evidence base it draws on. A high-DHA algae softgel marketed for pregnancy or cognition is not a substitute for an EPA-predominant product used for mood or inflammation, and vice versa.

Mechanism of Action

EPA works through several converging mechanisms — E-series resolvin synthesis, eicosanoid competition with arachidonic acid, NF-κB suppression, membrane integration, and PPAR-α-driven triglyceride reduction — which together explain its inflammation, cardiovascular, and mood evidence.

EPA exerts its effects through several converging molecular mechanisms. Understanding them clarifies why one fatty acid appears in evidence reviews for cardiovascular, inflammatory, and mood outcomes.

1 · E-series resolvins and the resolution of inflammation. EPA is the substrate for a family of lipid signaling molecules — the E-series resolvins (RvE1, RvE2) and the precursor 18-HEPE — collectively part of the specialized pro-resolving mediator (SPM) class. SPMs do not merely suppress inflammation; they actively terminate it, promoting neutrophil clearance, macrophage efferocytosis (the orderly removal of dying cells), and the return of tissue to homeostasis. This resolution biology is the molecular basis for EPA's effects on chronic low-grade inflammation and on inflammatory joint disease.

2 · Competition with arachidonic acid in eicosanoid synthesis. EPA competes with arachidonic acid (an omega-6 fatty acid) for the cyclooxygenase (COX-1, COX-2) and lipoxygenase (LOX) enzymes. The eicosanoids produced from EPA — 3-series prostaglandins and thromboxanes, 5-series leukotrienes — are markedly less pro-inflammatory than the arachidonic-acid–derived 2-series prostaglandins (including PGE₂) and 4-series leukotrienes (including LTB₄). This is the classic acute anti-inflammatory mechanism and contributes to EPA's effects on platelet behavior and vascular tone.

3 · NF-κB pathway suppression. EPA inhibits IκB kinase activity, preventing the NF-κB transcription factor from translocating to the nucleus. The downstream result is reduced transcription of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and C-reactive protein — the molecular fingerprint of the chronic low-grade inflammation that links metabolic and cardiovascular disease.

4 · Membrane phospholipid incorporation. EPA is incorporated into the phospholipids of cell membranes, partially displacing arachidonic acid and changing membrane composition and the function of membrane-embedded receptors. EPA's membrane role is more about turnover for signaling than about long-term structural residence (the structural role belongs to DHA in neural and retinal tissue).

5 · PPAR-α activation and triglyceride reduction. EPA activates the nuclear receptor PPAR-α, upregulating hepatic β-oxidation genes and suppressing the synthesis of very-low-density lipoprotein (VLDL). The downstream effect is reduced hepatic VLDL secretion and accelerated clearance of circulating triglycerides — EPA's most reproducible metabolic effect, with consistent dose-dependent reductions of 15–30% in serum triglycerides at 2–4 g/day.

6 · Neurotransmitter modulation relevant to mood. EPA influences serotonin and dopamine signaling and modulates neuroinflammation, providing a plausible neurobiological context for the antidepressant signal seen specifically with EPA-predominant formulations.

EPA's mechanistic case is supported by human biomarker data (red-blood-cell Omega-3 Index, circulating SPMs, inflammatory cytokines, plasma triglycerides). The mechanistic evidence is strong by supplement-science standards; the open questions concern which mechanism dominates in which clinical context, not whether the mechanisms exist.

Evidence-Based Benefits

The EPA evidence record is unusual among supplements in that it contains a landmark positive cardiovascular trial alongside two large null cardiovascular trials. This page presents both, in the transparency tradition of NIH-ODS, Cochrane, and Examine.com. Each sub-section indicates the evidence character, the strongest individual studies, and the relevant limitations.

Dosage by Context

Supplement pure EPA is commonly used at 1–2 g/day; the REDUCE-IT cardiovascular benefit used 4 g/day prescription icosapent ethyl under physician supervision; the FDA guidance is ≤2 g/day EPA+DHA from supplements (total intake up to 3 g/day considered safe), with atrial-fibrillation risk rising at 4 g/day.

The right dose depends on the outcome and — critically for EPA — on whether the context is a self-directed supplement or a physician-supervised prescription. The table below summarizes the dose ranges supported by the strongest evidence cited above.

Key dose caveats.

• Supplement EPA is not prescription icosapent ethyl. The REDUCE-IT outcome data describe a 4 g/day prescription drug under physician supervision in a defined high-risk population and should not be transferred to an over-the-counter pure-EPA supplement at 1–2 g/day.
• At 4 g/day, atrial-fibrillation risk is increased. This is reproducible (REDUCE-IT and STRENGTH both reported it; STRENGTH more strongly). High-dose EPA should be used under physician supervision, particularly in people with a history of atrial fibrillation or other heart-rhythm disorders.
• The EFSA cardiovascular nutrition claim threshold is 250 mg/day of EPA+DHA combined; the ANVISA functional triglyceride-reduction claim requires at least 1,500 mg/day of EPA+DHA combined. These are blend thresholds — EPA-only formulations meet them when the combined dose is adequate.
• EPA:DHA ratio is not cosmetic. Match the ratio to your reason for taking it: EPA-predominant for mood and inflammation; balanced or EPA-skewed for triglycerides; DHA-predominant for structural/brain support (see the DHA sub-page).

Safety, Side Effects, and Drug Interactions

Common, mild side effects include a fishy-taste reflux or belching (especially with lower-purity products on an empty stomach) and gastrointestinal discomfort (nausea, loose stools, bloating). Most side effects are dose- and form-dependent; higher-quality forms taken with a fat-containing meal substantially reduce reflux.

Atrial fibrillation at high dose. As detailed in the Cardiovascular and Negative Findings sections above, 4 g/day doses have been associated with an approximately 1% absolute increase in atrial-fibrillation incidence in the STRENGTH trial (mixed EPA+DHA), with a smaller but reproducible signal in the pure-EPA REDUCE-IT trial. People with a history of atrial fibrillation, atrial flutter, or other heart-rhythm disorders should use high-dose EPA only under medical supervision.

Bleeding risk. Omega-3, including EPA, inhibits platelet aggregation in laboratory and short-term human studies. Reviews have concluded that clinically important bleeding has not been demonstrated in randomized trials at supplemental doses, including in patients on anticoagulants and antiplatelet agents. The theoretical concern remains, and patients taking anticoagulants in combination with high-dose EPA should inform their physician and have routine monitoring.

Drug interactions.

• Statins: combination is safe and is the explicit context of the REDUCE-IT trial.
• Antihypertensives: mild additive blood-pressure lowering is possible.
• Antidiabetic medications: mild additive glucose-lowering effect possible.
• Anticoagulants and antiplatelet agents: see "Bleeding risk" above — clinically important bleeding has not been demonstrated, but monitoring is reasonable.

Allergy. People with fish or shellfish allergy should avoid fish-derived and krill-derived oils and use an EPA-enriched algae oil instead, which is produced by closed-system fermentation and has no protein cross-reactivity with fish or shellfish allergens.

The supplement-vs-prescription line. The strongest EPA safety/efficacy data come from icosapent ethyl, a prescription drug. Self-directed high-dose EPA outside a clinical context — particularly at the 4 g/day level — is not equivalent to the supervised prescription use that generated the evidence, and the atrial-fibrillation signal is the reason this distinction matters for safety, not only for efficacy.

Sources — Fish First, Krill, Algae for Plant-Based Diets

EPA is obtained from marine sources and, for plant-based eaters, from EPA-enriched microalgae. The hierarchy below corrects the common misconception that EPA is "algae-limited" — fish and fish oil are the primary source.

Source bottom line. EPA is fish-first: oily fish and fish oil are the primary dietary source and the basis of most of the evidence. Krill oil offers phospholipid-bound EPA at lower concentration. EPA-enriched algae oil is the legitimate vegan/vegetarian alternative — secondary in the hierarchy and frequently DHA-dominant unless an EPA-enriched strain is chosen. ALA from flaxseed and other plants is an inefficient indirect route, not a substitute. For quality criteria (third-party purity certification, EPA-milligram disclosure, freshness/TOTOX, form transparency), see the omega-3 hub, which covers these in detail for the whole family.

Tags

Body Systems: Cardiovascular · Cellular Renewal · Mood & Stress Response · Immune System

Mechanisms: Cell membrane phospholipid integration · Specialized pro-resolving mediators (SPMs) biosynthesis · Competitive metabolism with arachidonic acid · PPAR-α activation · NF-κB signaling inhibition

Evidence Tier: Mixed evidence (medium-large RCT supported · long-term hard-outcome trials absent)

Dosage Range: 1-2 g/d pure EPA (supplement · general) · 4 g/d prescription icosapent ethyl (REDUCE-IT · physician-supervised CVD indication) · ≤2 g/d EPA+DHA from supplements per FDA (total intake up to 3 g/d considered safe) · ≤5 g/d EFSA tolerable upper

Last Evidence Review: 2026-06-04 · Reviewed by Evidence Synthesis Lead + Regulatory Compliance Lead

Related Goals

• heart-health
• inflammation-relief
• longevity-stack

Related Lifestyles

• senior-60-plus
• athletic-performance

Related Ingredients

• omega-3
• dha
• fish-oil
• algae-oil
• krill-oil
• ala

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

Cardiovascular Outcomes

1. PMID 30415628 · Bhatt DL et al. (2019) · "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia" (REDUCE-IT) · NEJM · n=8,179 statin-treated, elevated TG · 4 g/day pure EPA (icosapent ethyl) · primary CV composite HR 0.75 (−25%) over median 4.9 y
2. PMID 30415637 · Manson JE et al. (2019) · "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer" (VITAL) · NEJM · n=25,871 generally healthy · 1 g/day EPA+DHA · primary CV null (HR 0.92) · secondary MI reduced
3. PMID 33190147 · Nicholls SJ et al. (2020) · "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events" (STRENGTH) · JAMA · n=13,078 statin-treated high-risk · 4 g/day EPA+DHA carboxylic acid · primary null + atrial fibrillation HR ~1.69
4. PMID 37264945 · Triglyceride dose-response meta-analysis · 2–4 g/day EPA+DHA → 15–30% serum triglyceride reduction

Mood / Depression

5. PMID 31383846 · Liao Y et al. (2019) · meta-analysis of 26 RCTs n=2,160 · EPA-predominant (≥60%) or pure EPA ≤1 g/day antidepressant effect · DHA-predominant null · Translational Psychiatry
6. PMID 26978738 · Mocking RJT et al. (2016) · meta-analysis + meta-regression of 13 RCTs n=1,233 · higher EPA dose + concurrent antidepressant predict better outcomes · Translational Psychiatry
7. PMID 34493705 · 2021 correction to PMID 31383846

Inflammation / Joint

8. PMID 38922552 · Wang et al. (2024) · meta-analysis of RCTs in rheumatoid arthritis · tender joint count ↓ (SMD ≈ −0.59) + lipid/inflammatory markers improved; DAS28 not significant · omega-3 (EPA+DHA), not stratified by ratio · Clinical Rheumatology

Forms / Bioavailability

9. PMID 20638827 · Dyerberg J et al. (2010) · "Bioavailability of marine n-3 fatty acid formulations" · Prostaglandins Leukotrienes and Essential Fatty Acids · rTG 124% · TG 100% · EE 73%

Regulatory and Public-Health References (not counted in PMID total)

• FDA · Qualified health claim for EPA+DHA and coronary heart disease (≥0.8 g per serving) · supplement labels should not recommend exceeding 2 g/day EPA+DHA; total intake up to 3 g/day considered GRAS · icosapent ethyl (Vascepa) is a prescription drug for CV risk reduction in elevated-triglyceride adults
• EFSA Reg 432/2012 · "EPA and DHA contribute to the normal function of the heart" — at a daily intake of at least 250 mg EPA+DHA · ≤5 g/day EPA+DHA tolerable upper intake (EFSA 2012)
• ANVISA (Brazil) · IN 28/2018 Anexo V · authorized functional claim "Os ácidos graxos ômega 3 EPA e DHA auxiliam na redução dos triglicerídeos" — for supplements providing at least 1,500 mg EPA+DHA per day
• China NHC / SAMR · DHA and EPA recognized as n-3 PUFA nutrient sources; fish oil and DHA algae oil listed on the health-food raw-material directory (filing-based)
• AHA 2017 Scientific Statement · omega-3 bleeding risk · no clinically important bleeding demonstrated at supplemental doses

For the full omega-3 family evidence base — including DHA-specific brain/eye/pregnancy data, the AMD and Alzheimer's nulls, forms comparison (rTG/EE/TG/PL), and quality criteria — see the omega-3 cluster hub.

Related Pages

• Omega-3 (overview) — EPA, DHA, and ALA in one place; the full marine + plant evidence base, forms comparison, and quality criteria.
• DHA — the structural omega-3 monomer; brain, retina, and fetal development. EPA's complement, not its substitute.
• Fish oil — the primary dietary source of EPA and the largest clinical evidence base.
• Algae oil — the vegan/vegetarian alternative for direct EPA (choose an EPA-enriched strain) and DHA.
• Flaxseed (ALA) — the plant precursor; why ALA does not reliably substitute for direct EPA.

Educational Disclaimer

This page is educational reference content and is not medical advice. Discuss supplement use — and any high-dose or prescription EPA (icosapent ethyl) — with a qualified healthcare provider, particularly if you are pregnant, breastfeeding, take prescription medications, or have a history of atrial fibrillation, bleeding disorders, or other medical conditions.

Frequently Asked Questions

The questions below are the most-searched questions on EPA across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.